Recent publications
- Harnessing the Power of Artificial Intelligence to Enhance Drug Therapy Research January 14, 2026No abstractWilliam L Baker
- Concurrent Administration of Triazoles with Chemotherapeutic and/or Immunosuppressant Agents Known to Have Moderate-to-Severe Drug-Drug Interactions in Patients with Hematologic Malignancies Hospitalized for Invasive Aspergillosis January 13, 2026CONCLUSIONS: Concurrent administration of triazole with potential PK interactions with CT or IS agents occurred in most HM patients admitted for IA. Choosing alternative antifungals, therapeutic drug monitoring of triazoles or selective ISs, and dosage adjustment of CT/IS agents may mitigate the risk of adverse DDIs. New antifungal agents without serious DDIs with CT and/or […]Thomas J Walsh
- PCSK9 and ANGPTL3 Inhibitors in Homozygous Familial Hypercholesterolemia: A Meta-analysis of Randomized Clinical Trials January 7, 2026CONCLUSIONS: PCSK9 inhibitors have lower efficacy in reducing lipid levels in HoFH compared with ANGPTL3 inhibitors, with the greatest difference seen in patients with the negative LDLR genotype. Further studies are needed to clarify efficacy across LDLR functional variants.Ibadete Bytyçi
- Transdermal "Natural GLP-1" Dietary Supplements Violate Law and Place Patients at Risk January 2, 2026Consumers precluded from obtaining semaglutide or tirzepatide by clinicians or insurers are turning to natural "GLP-1" transdermal patches. The Dietary Supplement Health and Education Act specifies dietary supplement products must be swallowed, so all these products are illegal. We identified 24 transdermal patch dietary supplement products and 1 transdermal gel product with an average of […]C Michael White
- Co-administration of triazoles with calcineurin or mammalian target of rapamycin inhibitors in solid organ transplant patients hospitalized with invasive aspergillosis December 19, 2025CONCLUSIONS: Voriconazole was used nearly twice as frequently as isavuconazole, despite isavuconazole having more predictable pharmacokinetics and a lower propensity for severe drug-drug interactions versus voriconazole. The still-frequent use of isavuconazole may reflect its lower inhibition of CNIs and mTOR inhibitors. Resulting drug-drug interactions may be serious and dose adjustment and therapeutic drug monitoring are […]Barbara Alexander
- Continuing as Partners in Immunization: Building Immunization Confidence Through Communication, Education, and Resources December 19, 2025Immunizations are among the most effective public health measures, significantly reducing the prevalence of serious infectious diseases across the population. Their success is so profound that many in the United States have never witnessed the devastating effects of illnesses, such as measles, polio, or diphtheria. Despite this progress, the Centers for Disease Control and Prevention […]Jennifer E Girotto
- Engineering Nanoparticles to Modulate Extracellular Matrix and Immune Components of the Tumor Microenvironment in Cancer Immunotherapy December 11, 2025Cancer immunotherapy has emerged as a transformative strategy for treating malignancies by harnessing the body's immune system. However, its clinical efficacy is often limited by the complex and immunosuppressive nature of the tumor microenvironment (TME), which poses substantial barriers to therapeutic success. The TME comprises a variety of components, including immune cells, cancer-associated fibroblasts, abnormal […]Bao-Toan Dang
- Temporal Changes in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use in Patients with Chronic Kidney Disease and Type 2 Diabetes, 2012-2023: A US Cohort Study December 9, 2025CONCLUSIONS: These findings inform and contextualize future studies assessing cardiorenal outcomes for these and additional treatments, including finerenone, for individuals with CKD and type 2 diabetes.Catherine B Johannes
- Methods of identifying transthyretin amyloid cardiomyopathy in secondary data sources: a systematic review December 8, 2025CONCLUSIONS: Methods for identifying ATTR-CM in studies of secondary datasets were heterogeneous. Future research should focus on optimizing ATTR-CM identification algorithms and performing validation studies.Craig I Coleman
- Coccidioidomycosis-Attributable Death in the United States: An Analysis of Cases Reported on Death Certificates, 2018-2023 November 26, 2025Contemporary data on coccidioidomycosis death rates are sparse. Death certificate data for 2018-2023 from the US National Vital Statistics System were evaluated. Coccidioidomycosis deaths were identified using diagnosis codes B38.x listed anywhere on certificates. Deaths and age-adjusted mortality rates (AAMRs)/1,000,000 people, with 95% confidence intervals (CIs), were determined. We identified 1760 coccidioidomycosis-attributable deaths (AAMR = […]Huiqiao Fan
- Aspergillosis-Attributable Mortality in the United States: Analysis of Death Certificate Data November 24, 2025CONCLUSIONS: Among patients with a death certificate with aspergillosis, primary attributable mortality was 22.0%. Our results may be useful as experts seek to better understand the true epidemiology of aspergillosis, develop efforts to raise disease awareness, and reduce aspergillosis-related mortality.Thomas J Walsh
- Lutetium Lu 177 vipivotide tetraxetan: A literature review November 11, 2025To review pharmacology, pharmacokinetics, therapeutic use, product safety/description and perspectives on use of lutetium Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer (mCRPC). Data sources: A literature search was conducted using PubMed/Dynamed (October 2013-May 2025), limited to English language, humans, clinical trials, case reports, and guidelines. Data summary: Lutetium Lu 177 vipivotide […]Grace Morrison
- Utilizing Machine Learning to Identify Predictors of Corticosteroid Discontinuation 1-Year After Adult Heart Transplant November 11, 2025CONCLUSIONS: In a large national database, utilizing novel ML modeling techniques, we identified annual transplant center volume, donor ischemia time, and LVAD use at the time of HT as the best predictors of CS discontinuation 1 year after HT.Caroline Chen
- Continuing as Partners in Immunization: Updates to Practice and Legislation for Pediatric Pharmacy Immunizations October 20, 2025No abstractJennifer E Girotto
- Infrared thermal mapping of osteotomy: influence of drill diameter and implant system October 20, 2025CONCLUSION: The study found significant variations in temperature increase based on the implant system and drill diameter. Baseline temperature, pilot drill, and second drill temperatures were significant predictors of the third final drill temperature, while the implant system itself was not a significant factor.Daniel Alvitez-Temoche
- Effectiveness and Safety of Rivaroxaban Versus Warfarin in Venous Thromboembolism Patients with Comorbid Obstructive Sleep Apnea: A Retrospective Cohort Study October 15, 2025IntroductionObstructive sleep apnea (OSA) is prevalent in patients with venous thromboembolism (VTE). We sought to evaluate the effectiveness and safety of rivaroxaban versus warfarin in VTE patients with comorbid OSA.MethodsWe performed retrospective cohort analyses using the Optum^(®) de-identified Electronic Health Record data set (Optum^(®) EHR) from November 1, 2011 to June 30, 2023. We included […]Craig I Coleman
- Misuse of the unspecified coccidioidomycosis diagnosis code: An audit of electronic health records October 13, 2025Widespread use of the 'unspecified coccidioidomycosis' code (B38.9) may negatively impact provider reimbursement and complicate study of disease burden. We sought to determine the frequency of B38.9 use in routine practice and assess how often it could be changed to a more specific code, what code that might be, and reasons for its initial use. […]Craig I Coleman
- Effectiveness and Safety of Antibiotics in Kidney Transplant Recipients With Asymptomatic Bacteriuria: A Systematic Review and Meta-analysis of Randomized Controlled Trials September 29, 2025CONCLUSIONS: Current evidence does not support routine screening and treatment of posttransplant ASB in KTRs.Abdullah Tarik Aslan
- Healthcare Resource Utilization, Treatment Costs, and Mortality in Patients with Malignancies or Transplantation Who Develop Invasive Aspergillosis September 26, 2025Objectives: Invasive aspergillosis (IA) poses significant risks to patients with malignancies or transplantation; however, estimates of burden-of-illness in patients with IA are sparse. We sought to assess in-hospital and outpatient healthcare resource utilization, all-cause treatment costs, and mortality in patients admitted with IA with hematologic or non-hematologic malignancies, bone marrow transplant/hematopoietic cell transplantation (BMT/HCT), or […]Thomas J Walsh
- Cost-effectiveness of olorofim in the treatment of invasive aspergillosis in patients with limited suitable alternative treatment options: a US payer perspective August 27, 2025This study aimed to estimate the cost-effectiveness of treating invasive aspergillosis (IA) in patients with limited treatment options with either olorofim or currently available antifungal salvage therapy from a US payer perspective. A hybrid decision tree-Markov model with a one-year time horizon was used to estimate health economic outcomes. The model considered probabilities of treatment […]Thomas J Walsh